338 related articles for article (PubMed ID: 34002256)
1. Amorphous Solid Dispersions Containing Residual Crystallinity: Competition Between Dissolution and Matrix Crystallization.
Moseson DE; Corum ID; Lust A; Altman KJ; Hiew TN; Eren A; Nagy ZK; Taylor LS
AAPS J; 2021 May; 23(4):69. PubMed ID: 34002256
[TBL] [Abstract][Full Text] [Related]
2. Amorphous solid dispersions containing residual crystallinity: Influence of seed properties and polymer adsorption on dissolution performance.
Moseson DE; Parker AS; Beaudoin SP; Taylor LS
Eur J Pharm Sci; 2020 Apr; 146():105276. PubMed ID: 32092362
[TBL] [Abstract][Full Text] [Related]
3. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
4. Elucidating the effect of crystallization on drug release from amorphous solid dispersions in soluble and insoluble carriers.
Ojo AT; Ma C; Lee PI
Int J Pharm; 2020 Dec; 591():120005. PubMed ID: 33132149
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Amorphous Solid Dispersions and Identification of Low Levels of Crystallinity by Transmission Electron Microscopy.
S'ari M; Blade H; Cosgrove S; Drummond-Brydson R; Hondow N; Hughes LP; Brown A
Mol Pharm; 2021 May; 18(5):1905-1919. PubMed ID: 33797925
[TBL] [Abstract][Full Text] [Related]
6. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
7. The application of temperature-composition phase diagrams for hot melt extrusion processing of amorphous solid dispersions to prevent residual crystallinity.
Moseson DE; Taylor LS
Int J Pharm; 2018 Dec; 553(1-2):454-466. PubMed ID: 30393199
[TBL] [Abstract][Full Text] [Related]
8. Impact of Processing Methods on the Physico-chemical Properties of Posaconazole Amorphous Solid Dispersions.
He R; Lamm MS; Brunskill A; Axnanda S; Li Y
Pharm Res; 2024 Jan; 41(1):141-151. PubMed ID: 38040879
[TBL] [Abstract][Full Text] [Related]
9. Formulation and Processing Strategies which Underpin Susceptibility to Matrix Crystallization in Amorphous Solid Dispersions.
Moseson DE; Hiew TN; Su Y; Taylor LS
J Pharm Sci; 2023 Jan; 112(1):108-122. PubMed ID: 35367246
[TBL] [Abstract][Full Text] [Related]
10. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
[TBL] [Abstract][Full Text] [Related]
11. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.
Saboo S; Kestur US; Flaherty DP; Taylor LS
Mol Pharm; 2020 Apr; 17(4):1261-1275. PubMed ID: 32134677
[TBL] [Abstract][Full Text] [Related]
12. Novel supercritical carbon dioxide impregnation technique for the production of amorphous solid drug dispersions: a comparison to hot melt extrusion.
Potter C; Tian Y; Walker G; McCoy C; Hornsby P; Donnelly C; Jones DS; Andrews GP
Mol Pharm; 2015 May; 12(5):1377-90. PubMed ID: 25730138
[TBL] [Abstract][Full Text] [Related]
13. Manufacturing Amorphous Solid Dispersions with a Tailored Amount of Crystallized API for Biopharmaceutical Testing.
Theil F; Milsmann J; Anantharaman S; van Lishaut H
Mol Pharm; 2018 May; 15(5):1870-1877. PubMed ID: 29648833
[TBL] [Abstract][Full Text] [Related]
14. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
[TBL] [Abstract][Full Text] [Related]
15. Detecting Crystallinity in Amorphous Solid Dispersions Using Dissolution Testing: Considerations on Properties of Drug Substance, Drug Product, and Selection of Dissolution Media.
Purohit HS; Zhang GGZ; Gao Y
J Pharm Sci; 2023 Jan; 112(1):290-303. PubMed ID: 36306864
[TBL] [Abstract][Full Text] [Related]
16. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
Chavan RB; Lodagekar A; Yadav B; Shastri NR
Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
[TBL] [Abstract][Full Text] [Related]
17. Congruent release of drug and polymer: A "sweet spot" in the dissolution of amorphous solid dispersions.
Saboo S; Mugheirbi NA; Zemlyanov DY; Kestur US; Taylor LS
J Control Release; 2019 Mar; 298():68-82. PubMed ID: 30731151
[TBL] [Abstract][Full Text] [Related]
18. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
Xie T; Taylor LS
Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
[TBL] [Abstract][Full Text] [Related]
19. Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions.
Hiew TN; Zemlyanov DY; Taylor LS
Mol Pharm; 2022 Feb; 19(2):392-413. PubMed ID: 34494842
[TBL] [Abstract][Full Text] [Related]
20. Absorptive Dissolution Testing: An Improved Approach to Study the Impact of Residual Crystallinity on the Performance of Amorphous Formulations.
Hate SS; Reutzel-Edens SM; Taylor LS
J Pharm Sci; 2020 Mar; 109(3):1312-1323. PubMed ID: 31765652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
